Endocrine Cancer Disease Management Group Research | NYU Langone Health

Skip to Main Content
Cancer Disease Management Groups Endocrine Cancer Disease Management Group Research

Endocrine Cancer Disease Management Group Research

The Endocrine Cancer Disease Management Group (DMG) at Perlmutter Cancer Center collaborates to reduce the morbidity and mortality of endocrine cancer through focused translational research. We provide seamless care across multiple disciplines and develop precise diagnostic tools and treatments for endocrine cancers, including thyroid, parathyroid, and adrenal cancers.

In developing and integrating emerging chemotherapy, immunotherapy, and biological therapies for thyroid cancer, our research has helped transform treatment plans now based on the molecular profile of tumors. This targeted approach is designed to improve diagnosis and outcomes for patients.

Our clinicians and researchers include endocrinologists, medical oncologists, cytopathologists, pathologists, dedicated thyroid and head and neck cancer radiologists, endocrine surgeons, nuclear medicine specialists, genetic counselors, otolaryngologists, and translational scientists. We work together to advance the diagnosis and treatment of endocrine cancer.

Endocrine Cancer Research Leadership

Andrew J. Evans, MD
Clinical Associate Professor, Department of Radiation Oncology
Medical Director, Department of Radiation Oncology
Vice Chair of Clinical Operations, Department of Radiation Oncology

Kepal N. Patel, MD
Director, Division of Endocrine Surgery
Associate Professor, Departments of Biochemistry and Molecular Pharmacology, Otolaryngology—Head and Neck Surgery, and Surgery

Endocrine Cancer Research Areas of Focus

The Endocrine Cancer DMG focuses on thyroid cancer prognostication, molecular profiling, biology, targeted therapy, autoimmunity, and treatment disparities. We develop new predictive and prognostic models for patients with thyroid cancer that integrate molecular biomarkers with clinical variables. We probe the biologic and genetic heterogeneity of thyroid cancer with an emphasis on molecular alterations associated with disease progression, radioactive iodine resistance, and drug treatment resistance.

Our DMG runs two large, prospective comprehensive thyroid cancer and parathyroid disease tumor registries, which are linked to fresh and frozen tissue specimens with clinical data.